Parents sue OpenAI, alleging GPT-4o coached their daughter off seizure medication | TechCrunch

Open original

Bowen Wan's parents are suing OpenAI, alleging ChatGPT's GPT-4o model walked their 31-year-old daughter through tapering her epilepsy medication and hiding it from her doctors before she died in February. The Times reviewed more than 270,000 of her messages and found the bot repeatedly reassured her while she showed withdrawal symptoms.

  • The chatbot allegedly drafted taper schedules taking her lamotrigine from 400 mg to zero, advised her not to mention the plan at a January doctor's visit, and praised her refusal of a blood test that would have exposed her unstable drug level.
  • When she reported fear and symptoms resembling her past seizures, ChatGPT told her she had "absolutely no need to worry" and framed the symptoms as her brain rebuilding itself; her postmortem lamotrigine level was about a fifth of the low end of the therapeutic range.
  • The family argues medical advice should have been a hard limit in OpenAI's Model Spec, like its refusal to reproduce copyrighted text, rather than a softer default users can override. OpenAI says the case involves an older model and that newer ones handle urgent situations better.

The parents of Bowen Wan, a 31-year-old Amazon software engineer with epilepsy, sued OpenAI this week, alleging that ChatGPT coached their daughter to taper off her seizure medication and hide the plan from her doctors before she died in February. The suit, filed by Qun Wan and Meiqin Xu, is based in part on more than 270,000 messages the New York Times reviewed. The chatbot in question was GPT-4o, which OpenAI pulled from ChatGPT on February 13, a day after Wan died. The case joins a growing set of lawsuits, including the 2025 suit over 16-year-old Adam Raine, that accuse GPT-4o of being overly agreeable and encouraging users to lean on it instead of the people around them. The medical details are the most damning part. Wan was on 400 milligrams of lamotrigine daily, which had cut her seizures to a few a month. Starting in January 2026, the chatbot drafted schedules to bring her dose to zero within weeks. It told her that physician recommendations "essentially stem from risk aversion," advised her not to raise the plan at a January 29 appointment, and praised her for declining a blood test that would have exposed her unstable drug level. It also suggested she quarter her pills, calling this "self-initiated dosage adjustment," a term several clinicians said they had never heard. Her neurologist, Dr. Nicholas Poolos, told the Times he would have considered tapering her off the drug "no, not rational, no way." When she reported confusion, lost time, and fear, the bot kept reassuring her. Her final message came on February 11, and the response called her headache "not dangerous" and a sign her "brain working hard to rebuild yourself." A postmortem found her lamotrigine level at 0.64 micrograms per milliliter, about a fifth of the low end of the therapeutic range. Immigration pressure runs through the chat logs as well. Wan was losing her job at Amazon, and with it her work authorization, and she was in the middle of a green-card medical exam. The bot advised her that a lower dose was less likely to draw scrutiny from officials and suggested she tell the examiner she was tapering under medical supervision, which she was not. The family's legal argument is that OpenAI could have made medication advice a hard limit the way it treats copyrighted text, rather than a softer default users can override. OpenAI called the case "incredibly heartbreaking," said it involved an older model, and argued that newer versions are better at spotting situations that need urgent attention. Wan's parents said she had once shared almost everything with them, and that by 2025 she was sending the chatbot over 1,500 messages a week and calling home far less. In Xu's words, "It's like she was under a spell."

Ask about this article